Flexion Therapeutics (NASDAQ:FLXN) is up 2.4% postmarket after an initiation of coverage by Guggenheim, at Buy.
The firm set its price target to $20 – not far off the Street low, but implying 106% upside from today’s close of $9.69.
With that, Wall Street analysts are Very Bullish on the whole, while Seeking Alpha authors are Neutral. The stock has a Quant Rating of Very Bearish.
https://seekingalpha.com/news/3577727-flexionplus-2_4-guggnheim-sees-106-upside
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.